Senators McCain and Dorgan introduced some new legislation today that proposes to more closely regulate the supplement industry in the wake of reports that many products contain designer steroids and other such nasties which aren’t disclosed to the public. Bud Selig just released a statement on it:
“On behalf of Major League Baseball, I would like to thank Senators
John McCain and Byron Dorgan for their efforts to broaden the Food and
Drug Administration’s regulatory authority over dietary supplements. We
fully support the proposed legislation designed to protect athletes and
consumers from dangerous, mislabeled and tainted over-the-counter
supplements. The continued leadership of Senators McCain and Dorgan has
made an impact on this important issue.”
That’s all good, but if Selig really believed that mislabled and tainted over-the-counter supplements were a problem, why didn’t he buy J.C. Romero’s defense? Romero, you’ll recall, was suspended 50 games for taking something he bought from a GNC store which both he and the MLBPA thought was OK, and contained no evidence that it had bad stuff in it on the label, but turned out to have a banned hormone in it. Baseball didn’t think that got him off the hook and he served his suspension because, according to Major League Baseball, he was “negligent.”
If baseball really thinks guys like Romero were “negligent” then you’d think they’d issue a statement saying that the new law is unnecessary.
UPDATE: Just had a conversation with someone at Major League Baseball. Their view — which makes a good deal of sense, I’ll admit — is that the drug policy sort of has to take the kind of zero-tolerance approach that was taken in the Romero case, or else enforcement actions are going to be prone to a bunch of “I didn’t know what I was taking” defenses, rendering the policy largely ineffective. Ultimately, the issue is whether a player — despite his intentions — competed in a game with a banned substance in his system. I can see that. Baseball’s drug policy, while having multiple purposes, should probably have “making sure athletes are competing on a level playing field” as its top priority.
But one question I do have is that, if that’s the case, what’s the point of even having an appeals and arbitration process like the one Romero went through in the first place? Why not just a test-positive-no-appeal kind of system? Or at the most an appeals process that only scrutinizes the science of it all, such as whether the test itself was wrongly administered or whether the samples were tainted or what have you?
Nick Cafardo provides this interesting nugget in his Sunday notes column at the Boston Globe …
Hanley Ramirez, 1B-DH, Red Sox — There’s now talk in the front office that Dave Dombrowski is trying to move Ramirez in a deal. The Mariners, Orioles, and Angels seem to be the targets, and all three make sense.
Cafardo notes that “there are huge hurdles to cross” before a trade could happen — like how much of Hanley’s remaining salary the Red Sox would have to eat and what positions the soon-to-be 32-year-old is able to play defensively at this point in his career.
Boston’s higher-ups have asked Ramirez to learn first base and drop 20 pounds this winter. Whatever team is looking to acquire him would probably have to be comfortable with him serving primarily as a designated hitter.
Hanley is owed $68.2 million over the next three seasons and he carries a $22 million vesting option for 2019. He batted just .249/.291/.426 in 105 games this past year.
Ben Zobrist posted a cool .809 OPS (120 OPS+) in 126 games this summer between Oakland and Kansas City while appearing defensively at second base, third base, and both corner outfield positions.
His steady bat and defensive versatility make him a fit for just about every club in Major League Baseball, and the defending National League champions are among the teams in hot pursuit …
It’s a little odd to see the rebuilding Braves listed there given that Zobrist is 34 years old, but Rosenthal says the interest stems from a “desire for him to serve as [a] model for younger players” as the club prepares to open a new ballpark in 2017. Wasn’t that supposed to be Nick Markakis‘ job?
Zobrist and his agent Alan Nero are believed to be seeking a four-year deal.
Hey, the hot stove is finally generating some real fire …
CBS Sports’ Jon Heyman reports that the Tigers have agreed to terms on a contract with free agent starter Jordan Zimmermann. It’s a five-year deal worth around $110 million, per Jon Morosi of FOX Sports.
This should have a domino effect on a loaded starting pitching market. David Price, Zack Greinke, Johnny Cueto, Mike Leake, and Jeff Samardzija are just a few of the names still out there.
Zimmermann, 29, posted a 3.66 ERA, 1.21 WHIP, and 164/39 K/BB ratio in 201 2/3 innings this past season for the Nationals. He had a 2.66 ERA in 2014 and threw a no-hitter on the final day of the regular season.
Zimmermann’s free agency is tied to draft pick compensation because he rejected a one-year, $15.8 million qualifying offer from Washington, but the Tigers finished with one of the 10-worst win-loss records in 2015 so their first-round pick in 2016 is protected. Detroit will give up its second-round pick instead.
Here’s a pretty good way to finally break out of that turkey-induced Thanksgiving tryptophan coma.
It’s a compilation of the 10 longest home runs from the 2015 season, with MLB.com’s Statcast technology providing data along the path of each blast …